10-Q: Integrated BioPharma Reports Q2 Loss Amid Sales Decline

Integrated BioPharma, Inc. reported a net loss for the quarter and six months ended December 31, 2025, driven by significant sales decreases and margin erosion.

Summary

• Net sales for the six months ended December 31, 2025, decreased by $2,262 thousand, or 8.6%, to $23,969 thousand, compared to $26,231 thousand in the prior year.
• The company recorded an operating loss of $751 thousand for the six months ended December 31, 2025, a significant decline from an operating income of $692 thousand in the same period last year.
• A net loss of $639 thousand was reported for the six months ended December 31, 2025, compared to a net income of $375 thousand in the prior year.
• Gross profit decreased by $1,494 thousand, from $2,542 thousand in the six months ended December 31, 2024, to $1,048 thousand in the current period.
• Cost of sales as a percentage of net sales increased to 95.6% for the six months ended December 31, 2025, from 90.3% in the prior year.
• Cash at the end of the period increased to $5,314 thousand as of December 31, 2025, from $3,615 thousand as of June 30, 2025.
• Net cash provided by operating activities significantly increased to $1,918 thousand for the six months ended December 31, 2025, from $858 thousand in the prior year.
• Working capital decreased slightly to $14,278 thousand as of December 31, 2025, from $14,515 thousand as of June 30, 2025.
• Two major customers, Life Extension and Herbalife, accounted for approximately 89% of consolidated net sales for the six months ended December 31, 2025.
• The Board of Directors adopted an Equity Incentive Plan in December 2025, authorizing 7,500,000 shares, and issued 526,500 stock options to officers and employees.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative report due to significant declines in sales, gross profit, and a shift to net operating and net losses. While cash flow from operations improved, the underlying profitability issues, high customer concentration, and ongoing lease negotiation contribute to a challenging outlook.

Positives

• Cash balance increased to $5,314 thousand as of December 31, 2025, from $3,615 thousand as of June 30, 2025.
• Net cash provided by operating activities significantly improved to $1,918 thousand for the six months ended December 31, 2025, compared to $858 thousand in the prior year.
• Selling and administrative expenses decreased by $51 thousand, or approximately 3%, for the six months ended December 31, 2025.
• Interest income, net, increased to $73 thousand for the six months ended December 31, 2025, from $25 thousand in the prior year, attributed to lower financing costs and higher cash balances.
• The company has $4,500 thousand available under its credit lines.
• Management believes current operations and the revolving credit facility will support working capital requirements at least through February 11, 2027.

Negatives

• Consolidated net sales decreased by 8.6% to $23,969 thousand for the six months ended December 31, 2025, compared to $26,231 thousand in the prior year.
• The company reported an operating loss of $751 thousand for the six months ended December 31, 2025, a significant deterioration from an operating income of $692 thousand in the prior year.
• A net loss of $639 thousand was reported for the six months ended December 31, 2025, compared to a net income of $375 thousand in the prior year.
• Gross profit declined by $1,494 thousand for the six months ended December 31, 2025, indicating reduced profitability.
• Cost of sales as a percentage of net sales increased to 95.6% from 90.3%, reflecting margin erosion.
• Sales in the Other Business Lines Segment decreased significantly by 44.5% ($706 thousand) due to decreased sales from a major customer who represented 51% of that segment's net sales in the prior year.
• High customer concentration remains a concern, with two major customers accounting for approximately 89% of consolidated net sales for the six months ended December 31, 2025.

Risks

• High customer concentration: Approximately 89% of consolidated net sales for the six months ended December 31, 2025, were derived from two major customers in the Contract Manufacturing Segment. The loss of any significant customer could have a material adverse effect on operations.
• Economic conditions: Inflation, tariffs, and tightened labor markets may negatively impact margins by increasing operating costs and potentially reducing consumer disposable income, thereby decreasing customer orders.
• Pricing pressure: The company may not be able to timely increase selling prices to customers to offset rising costs from suppliers and its own operating expenses.
• Union contract expiration: Approximately 77% of employees are covered by a union contract expiring on August 31, 2026, which could lead to labor negotiations and potential disruptions.
• Competition: Risks include loss of market share and introduction of competing products by other companies.
• Regulatory changes: Changes in the pharmaceutical manufacturing and nutraceutical industries, as well as regulatory obstacles to new technologies or products, could impact the business.
• Availability of qualified personnel: The company faces risks related to the availability of qualified personnel.
• Supplier reliance: The loss of any significant suppliers could adversely affect operations.
• Legal proceedings: The company is subject to claims by third parties, and any adverse outcome could materially affect liquidity, financial condition, and cash flows.

Future Outlook

The company is focusing its efforts to improve operational efficiency and reduce spending to positively impact expense levels and gross margin. It plans to continue focusing on core businesses, maintain its cost structure in line with sales, and expand its customer base to reduce reliance on its two significant customers. Management acknowledges that it may not be able to timely increase selling prices to customers to offset rising operating costs due to various economic factors, including tariffs and inflation, which could also impact consumer spending and order volumes. The company is also evaluating the impact of recently issued accounting standards updates (ASU 2023-09, ASU 2024-03, ASU 2025-05).

Management Comments

• "We are focusing our efforts to improve operational efficiency and reduce spending that may have an impact on expense levels and gross margin."
• "We will continue to focus on our core businesses and push forward in maintaining our cost structure in line with our sales and expanding our customer base."
• "We believe that this focus may reduce our reliance on our two significant customers."
• "We have seen a slight negative impact in our margins due to inflation and tightened labor markets as we strive to increase prices to our customers as our operating costs increase."
• "We may not be able to timely increase our selling prices to our customers resulting from price increases from our suppliers due to various economic factors, including tariffs and other inflationary costs, labor and shipping costs and our own increases in shipping, labor and other operating costs."
• "Our results of operations may also be affected by economic conditions, including tariffs and other inflationary pressures, that can impact consumer disposable income levels and spending habits, thereby reducing the orders we may receive from our significant customers."
• "Management believes that operations, together with the revolving credit facility will support our working capital requirements at least through the period ending February 11, 2027."

Industry Context

StockSavvy.ai notes that the nutraceutical and contract manufacturing industries are characterized by competitive pressures and sensitivity to economic factors such as inflation and consumer spending habits. Integrated BioPharma's significant decline in sales and profitability, coupled with its high customer concentration, highlights vulnerabilities in a market that demands agility and diversified client portfolios. The company's stated efforts to improve operational efficiency and expand its customer base are critical strategic imperatives for navigating these industry challenges and mitigating future risks.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or industry benchmarks to assess Integrated BioPharma's performance against global standards or direct competitors.

Corporate Governance

Legal Proceedings

• The company is subject to claims by third parties under various legal theories from time to time. However, it is not currently aware of any legal proceedings or claims that are believed to have a material adverse effect on its business, financial condition, or operating results.

Related Party Transactions

• The company leases warehouse and office facilities from Vitamin Realty Associates, LLC, which is 100% owned by the estate of the company's former chairman, a major stockholder, and certain family members who are Co-Chief Executive Officers and directors.
• Operating lease liabilities with Vitamin Realty were $70 thousand as of December 31, 2025, and $485 thousand as of June 30, 2025.
• Rent expense and lease amortization costs for this related party lease were $347 thousand for the three months ended December 31, 2025, and $710 thousand for the six months ended December 31, 2025.
• The lease with Vitamin Realty was renewed, extending the termination date from January 31, 2026, to January 31, 2031, with an additional annual commitment of approximately $1,101 thousand in the first year.

Stakeholder Impact

• Shareholders: Negative impact due to reported net loss, decreased sales, and operating loss. Potential future dilution from the newly adopted Equity Incentive Plan.
• Employees: Approximately 77% of employees are unionized, with a contract expiring in August 2026, indicating potential for future labor negotiations. Stock options were granted to officers and employees.
• Customers: High customer concentration poses a risk, as a reduction in orders or loss of major customers could significantly impact the company's financial performance.
• Suppliers: The company's inability to timely increase selling prices to customers to offset rising supplier costs could strain supplier relationships or impact margins.
• Creditors: While cash flow from operations improved and credit lines are available, declining profitability could be a long-term concern for creditors.

Next Steps

• Complete negotiations with Vitamin Realty for a long-term lease renewal for warehouse and office space.
• Focus on improving operational efficiency and reducing spending to impact expense levels and gross margin.
• Expand the customer base to reduce reliance on the two significant customers.
• Evaluate the impact of new accounting standards (ASU 2023-09, ASU 2024-03, ASU 2025-05) on financial statements and disclosures.
• Engage in union contract renewal negotiations for approximately 77% of employees, with the current contract expiring on August 31, 2026.

Key Dates

Recommendation

The significant decline in sales, gross profit, and the shift from profitability to substantial losses for the quarter and six-month period are strong indicators of deteriorating operational performance. While cash flow from operations improved, this was largely due to changes in working capital rather than underlying profitability. The high customer concentration and ongoing inflationary pressures present considerable risks. The renewed related-party lease with a substantial annual commitment further adds to fixed costs without clear revenue growth. These factors suggest a challenging outlook for the company's financial health and stock performance, warranting a 'sell' recommendation.

Keywords

Integrated BioPharma, nutraceuticals, contract manufacturing, SEC filing, 10-Q, financial results, operating loss, customer concentration, liquidity, stock options, related party lease, vitamins, nutritional supplements